Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Table 4 Reason for change of recommendation

	Low-risk group (N = 154)	Non-low-risk group (N = 67)
Number of patients with decision change, n	23	22
Reasons^a for decision change, n:
Recurrence score	23 (100%)	21 (95%)
Opinion of tumor board changed	1 (4%)	1 (5%)
Patient preference	3 (13%)	1 (5%)
Other	2 (9%)	1 (5%)

^aMore than one reason for changing the treatment decision were possible
Further factors analyzed and never found to be a reason for change of recommendation after second tumor board were: Tumor board composition change, new medical information

ISSN: 1471-2407